Antiretroviral and Immunosuppressive Drug-Drug Interactions in Human Immunodeficiency Virus-Infected Liver and Kidney Transplant Recipients

Transplantation Proceedings

Volumn 41, Issue 9, 2009, Pages 3796-3799

  Marfo, K ^a   Greenstein, S ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIMETABOLITE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; EVEROLIMUS; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; INVERASE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RAPAMYCIN; REYETAZ; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TACROLIMUS; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ACUTE GRAFT REJECTION; ANEMIA; ARTICLE; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INHIBITION; DRUG METABOLISM; GRAFT RECIPIENT; GRANULOCYTOPENIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY GRAFT; LIFE EXPECTANCY; LIVER TRANSPLANTATION; MORTALITY; NAUSEA; PRIORITY JOURNAL; TREATMENT INDICATION; VOMITING;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; HALF-LIFE; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIVER DISEASES; LIVER TRANSPLANTATION; SURVIVORS;

EID: 71749116885     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.186     Document Type: Article

References (20)

1. Palella Jr. F.J., Delaney K.M., and Moorman A.C. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (1998) 853
2. Stock P.G., Roland M.E., and Carlson L. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 76 (2003) 370
3. Roland M.E., and Stock P.G. Review of solid-organ transplantation in HIV-infected patients. Transplantation 75 (2003) 425
4. Winston J., and Klotman P. Are we missing an epidemic of HIV associated nephropathy?. J Am Soc Nephrol 7 (1996) 1
5. Lam M., and Park M. HIV-associated nephropathy-beneficial effect of zidovudine therapy. N Engl J Med 323 (1990) 1775
6. Abbot K.C., Swanson S.J., and Agadoa L.Y. HIV infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 15 (2004) 1633
7. Tan H.P., Kaczorowski D.J., and Basu A. Living-related donor transplantation in HIV+ recipients using alemtuzumab precondition and steroid-free tacrolimus monotherapy: as single center experience. Transplantation 78 (2004) 1683
8. Gruber S.A., Doshi M.D., and Cincotta E. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation 86 (2008) 269
9. Roland M.E., Barin B., and Carlson L. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 8 (2008) 355
10. Hammer S.M., Eron Jr. J.J., and Reiss P. Treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA panel. JAMA 300 (2008) 555
11. Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Exp Op Drug Met Toxi 3 (2007) 583
12. Jain A.K., Venkatarmanan S., and Shapiro R. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 8 (2002) 841
13. Jan A.B., Venkataramanan R., and Eghtesad B. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 9 (2003) 954
14. Frassetto L., Baluom M., and Jacobsen W. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus infected liver and kidney transplant recipients. Transplantation 80 (2005) 13
15. Yoshimura R., Yoshimura N., and Ohyama A. The effect of immunosuppressive agents (FK-506, rapamycin) on renal P450 systems in rat models. J Pharm Pharmacol 51 (1999) 941
16. Jain A.K., Venkataramanan R., and Fridell J.A. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl 8 (2002) 838
17. Napoli K.L., and Kahan B.D. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection. Clin Chem 42 (1996) 1943
18. Bardsley-Elliot A., Noble S., and Foster R.H. Mycophenolate mofetil: a review of its use in the management of solid organ transplantation. Bio Drugs 12 (1999) 363
19. Fulton B., and Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51 (1996) 278
20. Margolis D., Heredia A., and Gaywee J. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 21 (1999) 362